Tag Archives: Aldeyra Therapeutics

Cantor Fitzgerald Reaffirms Their Buy Rating on Aldeyra Therapeutics

Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Aldeyra Therapeutics (NASDAQ: ALDX) today and set a price target of $23. The company’s shares opened today at $8.35. Piros wrote: “: We are reiterating our Overweight rating and 12-month

Aldeyra Therapeutics Gets a Hold Rating from Cowen & Co.

In a report issued on April 6, Ritu Baral from Cowen & Co. maintained a Hold rating on Aldeyra Therapeutics (NASDAQ: ALDX). The company’s shares closed on Friday at $7. According to TipRanks.com, Baral is a top 100 analyst with

Canaccord Genuity Remains a Buy on Aldeyra Therapeutics

Canaccord Genuity analyst John Newman maintained a Buy rating on Aldeyra Therapeutics (NASDAQ: ALDX) today and set a price target of $27. The company’s shares opened today at $8.85. Newman wrote: “We are updating our ALDX model, but our price

Cowen & Co. Remains a Buy on Aldeyra Therapeutics

In a report released today, Ritu Baral from Cowen & Co. reiterated a Buy rating on Aldeyra Therapeutics (NASDAQ: ALDX), with a price target of $20. The company’s shares opened today at $4.15, close to its 52-week low of $3.80.

Cowen & Co. Issues a Buy Rating on Aldeyra Therapeutics

In a report released today, Ritu Baral from Cowen & Co. reiterated a Buy rating on Aldeyra Therapeutics (NASDAQ: ALDX), with a price target of $20. The company’s shares opened today at $5.05. Baral said: “On its 4Q call, ALDX

Analysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (NASDAQ: ALDX), Spectrum Pharmaceuticals (NASDAQ: SPPI) and Omeros Corp (NASDAQ: OMER)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aldeyra Therapeutics (NASDAQ: ALDX), Spectrum Pharmaceuticals (NASDAQ: SPPI) and Omeros Corp (NASDAQ: OMER) with bullish sentiments. Aldeyra Therapeutics (NASDAQ: ALDX) In a